Buy Bulk CJC-1295 NO-DAC 2mg (No Promo Codes)

CJC-1295 NO-DAC is a synthetic peptide that contains the first 29 amino acids of the endogenous growth hormone-releasing hormone (GHRH).¹ Due to its shortened structure, the peptide is also known as modified growth releasing factor 1-29 (MOD GRF 1-29).¹ The molecular weight is 3365.87 g/mol. Originally, CJC-1295 was designed with a drug affinity complex (DAC) attached to it to help enhance the peptide’s half-life. This complex allows CJC-1295 to attach to albumin in the bloodstream, preventing clearance from the body.² However, this specific formulation of CJC-1295 does not have DAC, which allows the peptide to mimic a more appropriate physiological response during in vitro experiments. As CJC-1295 contains the sequence of GHRH, the peptide mainly functions to stimulate growth hormone release. In mice, one dose of CJC-1295 causes a two to 10 times increase in growth hormone levels. Compared to other peptides that also stimulate growth hormone release, CJC-1295 does not interfere with the natural release that occurs with circadian rhythm.³ Thus, there is interest in CJC-1295 as a treatment in growth disorders. One study created a mouse model with a knockout for GHRH, then treated them daily with CJC-1295 for five weeks. At the end of the study, these mice had normal measurements for length and body weight when compared to wild-type controls. This study highlights the ability of CJC-1295 to mimic the function of endogenous GHRH.¹ Other studies have shown that CJC-1295 enhances the secretion of insulin-like growth factor-1 (IGF-1) in animals.^4,5 Researchers hypothesize that CJC-1295 and other GHRH analogs may be preferred over using human growth hormone (hGH) for treating certain metabolic conditions.⁶

Blue Sky Peptide’s CJC-1295 NO-DAC is available as a white lyophilized powder at a concentration of 5 mg/vial. CJC-1295 NO-DAC is intended for in vitro scientific research.

References: 1. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. m J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-1294. 2. Jette L, Leger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRH) 1-29 - Albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-3058. 3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. 4. Campbell RM, Stricker P, Miller R, Bongers J, Liu W, Lambros T, Ahmad M, Felix AM, Heimer EP. Peptides. Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. 1994;15(3):489-495. 5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. 6. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.